In its 13F for Q1 2024 (holdings as of March 31, 2024, filed August 9, 2024), Stempoint Capital LP reported 45 stock positions worth $374.3 million . Its top holding was Roivant Sciences (ROIV) at 10.0% of the portfolio, followed by Crinetics Pharmaceuticals (CRNX, 7.8% ) and Syndax Pharmaceuticals (SNDX, 7.0% ). Compared with Q4 2023, it opened 17 new positions, sold out of 31, added to 16 and reduced 11. The biggest buy was Crinetics Pharmaceuticals (CRNX, shares +148% ) and the biggest sale an exit from Protagonist Therapeutics (PTGX).
Location NEW YORK, NY
CIK 0001952142
Portfolio Value $374.3M (Q1 2024) Holdings 45 stocks · $374.3M Holdings quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock % Of Portfolio ▼ Shares Held Total Value Change vs Q4 2023 ROIV Roivant Sciences Ltd. 3,553,844 $37.5M Add +63.8% CRNX Crinetics Pharmaceuticals Inc. 619,789 $29.0M Add +148.3% SNDX Syndax Pharmaceuticals Inc. 1,100,988 $26.2M Add +0.6% ARQT Arcutis Biotherapeutics Inc. 2,205,899 $21.9M Reduce -15.0% IMVT Immunovant Inc. 627,228 $20.3M Add +94.8% AUTL Autolus Therapeutics PLC 2,965,721 $18.9M Add +557.0% FOLD Amicus Therapeutics Inc. 1,547,141 $18.2M Add +79.3% CABA Cabaletta Bio Inc. 1,003,916 $17.1M Add +122.7% KALV Kalvista Pharmaceuticals Inc. 1,161,060 $13.8M Add +174.4% APLT Applied Therapeutics Inc. 2,017,016 $13.7M Add +122.3% LLY Eli Lilly & Co. 15,067 $11.7M No change MRUS Merus NV 233,871 $10.5M Reduce -53.4% ACLX Arcellx Inc. 140,267 $9.8M Reduce -55.3% VTGN Vistagen Therapeutics Inc. 1,848,582 $9.3M Add +3.3% TARS Tarsus Pharmaceuticals Inc. 222,253 $8.1M Add +617.2% PYXS Pyxis Oncology Inc. 1,794,195 $7.6M New INSM Insmed Inc. 272,448 $7.4M Add +57.0% TRML Tourmaline Bio Inc. 274,219 $6.3M New ANAB Anaptysbio Inc. 269,548 $6.1M Add +499.0% LRMR Larimar Therapeutics Inc. 740,877 $5.6M Reduce -5.4% IMTX Immatics NV 491,926 $5.2M Reduce -51.8% SLNO Soleno Therapeutics Inc. 115,833 $5.0M New SLRN Acelyrin Inc. 714,773 $4.8M Add +21.7% JANX Janux Therapeutics Inc. 121,642 $4.6M New BHVN Biohaven Ltd. 83,461 $4.6M Reduce -25.1% MLTX Moonlake Immunotherapeutics 90,647 $4.6M Reduce -46.0% ANNX Annexon Inc. 605,117 $4.3M Reduce -0.3% FULC Fulcrum Therapeutics Inc. 407,108 $3.8M Add +8.1% IDYA Ideaya Biosciences Inc. 87,393 $3.8M New JSPR Jasper Therapeutics Inc. 129,211 $3.8M New AVDL Avadel Pharmaceuticals Ltd. 223,660 $3.8M New IRON Disc Medicine Inc. 60,129 $3.7M Reduce -52.1% TSHA Taysha Gene Therapies Inc. 1,087,785 $3.1M New ATXS Astria Therapeutics Inc. 230,273 $2.7M Reduce -73.1% SYRE Spyre Therapeutics Inc. 62,253 $2.4M Reduce -83.6% BBOT Bridgebio Oncology Therapeut filed as HELIX ACQUISITION CORP II 200,000 $2.1M New EFTR Effector Therapeutics Inc. 132,793 $1.9M New NAMS Newamsterdam Pharma Co. NV 80,334 $1.9M New CGON CG Oncology Inc. 40,723 $1.8M New ACHL Achilles Therapeutics PL-ADR 1,385,750 $1.7M New PRAX Praxis Precision Medicines I 26,893 $1.6M New DNTH Dianthus Therapeutics Inc. 43,456 $1.3M New CRGX Cargo Therapeutics Inc. 51,126 $1.1M Add +90.2% KYTX Kyverna Therapeutics Inc. 41,000 $1.0M New TARA Protara Therapeutic Inc. 168,442 $675K New
Options reported separately and not counted above: CABA puts ($1.1M), XBI puts ($876K), ARQT puts ($516K), IMVT calls ($319K), MRUS puts ($213K), RNAM calls ($184K), CRNX puts ($158K), ACLX puts ($135K), BHVN puts ($122K), FOLD calls ($120K), VERA puts ($75K), KRYS puts ($71K), and 5 more.
Portfolio Sells Q4 2023 → Q1 2024 Portfolio Sells quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock Change vs Q4 2023 % Of Portfolio Change To Portfolio ▲ PTGX Protagonist Therapeutics Inc. Sold out 0.00% −3.17 BBIO Bridgebio Pharma Inc. Sold out 0.00% −2.76 ARGENX SE Sold out 0.00% −2.71 MRK Merck & Co. Inc. Sold out 0.00% −2.62 JNJ Johnson & Johnson Sold out 0.00% −2.58 ACLX Arcellx Inc. Reduce -55.3% 2.61% −2.08 TEVA PHARMACEUTICAL INDS LTD Sold out 0.00% −1.97 LNTH Lantheus Holdings Inc. Sold out 0.00% −1.82 LEGN Legend Biotech Corp.-ADR Sold out 0.00% −1.70 SYRE Spyre Therapeutics Inc. Reduce -83.6% 0.63% −1.57 MLTX Moonlake Immunotherapeutics Reduce -46.0% 1.22% −1.51 IMTX Immatics NV Reduce -51.8% 1.38% −1.51 SAGE Sage Therapeutics Inc. Sold out 0.00% −1.27 MDGL Madrigal Pharmaceuticals Inc. Sold out 0.00% −1.27 SPY SS SPDR S&P 500 ETF Trust-US Sold out 0.00% −1.27 ANIP Ani Pharmaceuticals Inc. Sold out 0.00% −1.27 ALPN Alpine Immune Sciences Inc. Sold out 0.00% −1.26 ETNB 89BIO Inc. Sold out 0.00% −1.23 CBAY Cymabay Therapeutics Inc. Sold out 0.00% −1.16 OLMA Olema Pharmaceuticals Inc. Sold out 0.00% −1.06 SCPH Scpharmaceuticals Inc. Sold out 0.00% −0.96 IRON Disc Medicine Inc. Reduce -52.1% 1.00% −0.95 ATXS Astria Therapeutics Inc. Reduce -73.1% 0.72% −0.95 FATE Fate Therapeutics Inc. Sold out 0.00% −0.91 MRUS Merus NV Reduce -53.4% 2.81% −0.90 KNSA Kiniksa Pharmaceuticals Ltd. Sold out 0.00% −0.87 NBIX Neurocrine Biosciences Inc. Sold out 0.00% −0.80 JASPER THERAPEUTICS INC Sold out 0.00% −0.79 MORPHOSYS AG Sold out 0.00% −0.74 EYPT Eyepoint Inc. Sold out 0.00% −0.60 ACIU Ac Immune SA Sold out 0.00% −0.59 CYTK Cytokinetics Inc. Sold out 0.00% −0.54 ARWR Arrowhead Pharmaceuticals Inc. Sold out 0.00% −0.49 AMAM New Ambrx Biopharma Inc. Sold out 0.00% −0.48 RAPT THERAPEUTICS INC Sold out 0.00% −0.39 OCUL Ocular Therapeutix Inc. Sold out 0.00% −0.34 AMLX Amylyx Pharmaceuticals Inc. Sold out 0.00% −0.33 STTK Shattuck Labs Inc. Sold out 0.00% −0.28 BHVN Biohaven Ltd. Reduce -25.1% 1.22% −0.06 ANNX Annexon Inc. Reduce -0.3% 1.16% +0.42 LRMR Larimar Therapeutics Inc. Reduce -5.4% 1.50% +0.54 ARQT Arcutis Biotherapeutics Inc. Reduce -15.0% 5.84% +3.58
Portfolio Buys Q4 2023 → Q1 2024 Portfolio Buys quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock Change vs Q4 2023 % Of Portfolio Change To Portfolio ▼ CRNX Crinetics Pharmaceuticals Inc. Add +148.3% 7.75% +5.36 AUTL Autolus Therapeutics PLC Add +557.0% 5.06% +4.27 ROIV Roivant Sciences Ltd. Add +63.8% 10.01% +3.44 APLT Applied Therapeutics Inc. Add +122.3% 3.66% +2.85 KALV Kalvista Pharmaceuticals Inc. Add +174.4% 3.68% +2.28 PYXS Pyxis Oncology Inc. New 2.04% +2.04 TARS Tarsus Pharmaceuticals Inc. Add +617.2% 2.16% +1.99 CABA Cabaletta Bio Inc. Add +122.7% 4.58% +1.82 IMVT Immunovant Inc. Add +94.8% 5.41% +1.76 TRML Tourmaline Bio Inc. New 1.68% +1.68 FOLD Amicus Therapeutics Inc. Add +79.3% 4.87% +1.57 ANAB Anaptysbio Inc. Add +499.0% 1.62% +1.36 SLNO Soleno Therapeutics Inc. New 1.32% +1.32 JANX Janux Therapeutics Inc. New 1.22% +1.22 IDYA Ideaya Biosciences Inc. New 1.02% +1.02 JSPR Jasper Therapeutics Inc. New 1.01% +1.01 AVDL Avadel Pharmaceuticals Ltd. New 1.01% +1.01 TSHA Taysha Gene Therapies Inc. New 0.83% +0.83 SNDX Syndax Pharmaceuticals Inc. Add +0.6% 7.00% +0.63 BBOT Bridgebio Oncology Therapeut New 0.56% +0.56 INSM Insmed Inc. Add +57.0% 1.97% +0.53 EFTR Effector Therapeutics Inc. New 0.51% +0.51 NAMS Newamsterdam Pharma Co. NV New 0.51% +0.51 CGON CG Oncology Inc. New 0.48% +0.48 ACHL Achilles Therapeutics PL-ADR New 0.46% +0.46 PRAX Praxis Precision Medicines I New 0.44% +0.44 DNTH Dianthus Therapeutics Inc. New 0.35% +0.35 FULC Fulcrum Therapeutics Inc. Add +8.1% 1.03% +0.34 KYTX Kyverna Therapeutics Inc. New 0.27% +0.27 TARA Protara Therapeutic Inc. New 0.18% +0.18 CRGX Cargo Therapeutics Inc. Add +90.2% 0.30% +0.14 VTGN Vistagen Therapeutics Inc. Add +3.3% 2.48% +0.12 SLRN Acelyrin Inc. Add +21.7% 1.29% +0.11
Options Activity Q4 2023 → Q1 2024 Security Type Change vs Q4 2023 Underlying Shares Value ▼ SPY SS SPDR S&P 500 ETF Trust-US put Sold out 6,500 $1.2Mbefore exit CABA Cabaletta Bio Inc. put New 500,000 $1.1M XBI SS SPDR S&P Biotech ETF put New 1,200,000 $876K IWM iShares Russell 2000 ETF put Sold out 1,500 $574Kbefore exit ARQT Arcutis Biotherapeutics Inc. put New 825,000 $516K ARKG ARK Genomic Revolution ETF put Sold out 5,000 $375Kbefore exit IRON Disc Medicine Inc. call Sold out 1,000 $371Kbefore exit IBB iShares Biotechnology ETF put Sold out 2,000 $360Kbefore exit MLTX Moonlake Immunotherapeutics put Sold out 500 $335Kbefore exit IMVT Immunovant Inc. call New 250,000 $319K ACLX Arcellx Inc. call Sold out 623 $283Kbefore exit QQQ Invesco QQQ Trust Series 1 put Sold out 600 $232Kbefore exit MRUS Merus NV put New 85,000 $213K RNAM Avidity Biosciences Inc. call New 75,000 $184K CRNX Crinetics Pharmaceuticals Inc. put New 175,000 $158K ACLX Arcellx Inc. put New 50,000 $135K BHVN Biohaven Ltd. put New 30,000 $122K FOLD Amicus Therapeutics Inc. call New 400,000 $120K VERA Vera Therapeutics Inc. put New 40,000 $75K KRYS Krystal Biotech Inc. put New 20,000 $71K AUTL Autolus Therapeutics PLC call New 250,000 $69K ROIV Roivant Sciences Ltd. put New 750,000 $56K TARS Tarsus Pharmaceuticals Inc. put New 50,000 $41K TARA Protara Therapeutic Inc. call New 87,900 $13K UTHR United Therapeutics Corp. call New 10,000 $11K
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings Quarter Positions 13F Reported Value Top Holdings Q2 2026 73 $577.9M TNGX, ABVX, RVMD, ERAS, TYRA Q1 2026 Amended 70 $520.3M SRRK, ABVX, SNDX, RVMD, IMVT Q4 2025 75 $582.7M ABVX, SRRK, CNTA, SNDX, GPCR Q3 2025 76 $495.9M ROIV, QURE, SRRK, IMVT, DNLI Q2 2025 50 $310.6M SNDX, IMVT, SRRK, CNTA, MDGL Q1 2025 52 $313.1M ROIV, SNDX, SRRK, ACLX, MRUS Q4 2024 48 $398.7M SNDX, ROIV, IMVT, MRUS, CRNX Q3 2024 50 $333.4M SNDX, ROIV, MRUS, IMVT, ARQT Q2 2024 Amended 42 $339.9M SNDX, ROIV, IMVT, CRNX, MRUS Q1 2024 Amended 45 $374.3M ROIV, CRNX, SNDX, ARQT, IMVT